Immune checkpoint receptor VISTA on immune cells is associated with expression of T-cell exhaustion marker TOX and worse prognosis in renal cell carcinoma with venous tumor thrombus.
PD-L1
Renal cell carcinoma
TOX
Thrombus
Tumor microenvironment
VISTA
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
26
06
2022
accepted:
24
08
2022
medline:
5
7
2023
pubmed:
31
8
2022
entrez:
30
8
2022
Statut:
ppublish
Résumé
The study aimed to determine the expression of VISTA and TOX within venous tumor thrombus and primary clear cell renal cell carcinoma (ccRCC) and to assess their prognostic value. The study enrolled 82 patients with ccRCC and coexisting venous tumor thrombus treated radically from 2012 to 2019 in two tertiary centers. Tissue microarrays were prepared and stained with respective antibodies. The expression of markers was assessed separately on tumor cells (TCs) and/or tumor-associated immune cells (TAICs). TOX expression was positively correlated with the percentage of VISTA-positive TAICs in venous thrombus (p = 0.011), but not in the primary tumor (p = 0.674). High TOX expression was associated with a higher percentage of PD-L1-positive TAICs in both compartments (p = 0.001, p = 0.011, respectively). Positive expression of VISTA on TAICs was associated with PD-L1 expression on TCs (p = 0.005) and TAICs (p = 0.004) in the primary tumor, and only with PD-L1 on TAICs in thrombus (p = 0.006). The presence of VISTA-positive TAICs in venous thrombus was significantly more common in females (p = 0.034), and positively correlated with metastases (p = 0.028), and tumor necrosis (p = 0.013). The cases with VISTA-positive TAICs in venous tumor thrombi had significantly shorter OS than VISTA-negative cases (p = 0.041). For the first time, we demonstrated the expression of VISTA- and TOX-positive TAICs in the venous tumor thrombus. We found the association between immune checkpoint receptors and T cell exhaustion markers in both tumor mass and venous thrombus. Finally, we demonstrated that abundance of VISTA-positive TAICs in venous tumor thrombus correlates with worse outcomes in ccRCC.
Identifiants
pubmed: 36042047
doi: 10.1007/s00432-022-04329-y
pii: 10.1007/s00432-022-04329-y
pmc: PMC10314835
doi:
Substances chimiques
B7-H1 Antigen
0
Biomarkers, Tumor
0
TOX protein, human
0
VSIR protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4131-4139Subventions
Organisme : Gdański Uniwersytet Medyczny
ID : 01-0395/08/643
Informations de copyright
© 2022. The Author(s).
Références
Front Oncol. 2021 Jun 23;11:646338
pubmed: 34249685
Curr Opin Oncol. 2019 May;31(3):194-199
pubmed: 30985497
Hum Immunol. 2014 Jul;75(7):614-20
pubmed: 24801648
Cell. 2017 May 4;169(4):736-749.e18
pubmed: 28475899
Ann Diagn Pathol. 2018 Jun;34:89-93
pubmed: 29661736
J Ultrason. 2015 Dec;15(63):438-42
pubmed: 26807301
Clin Cancer Res. 2015 Mar 1;21(5):1071-7
pubmed: 25538263
Front Immunol. 2021 Feb 02;11:622509
pubmed: 33633741
Urol Oncol. 2022 May;40(5):200.e1-200.e10
pubmed: 35346570
J Hematol Oncol. 2020 Jun 29;13(1):83
pubmed: 32600443
Front Oncol. 2019 Jun 14;9:490
pubmed: 31259150
J Immunother Cancer. 2019 May 28;7(1):139
pubmed: 31138299
Lung Cancer. 2017 Apr;106:1-7
pubmed: 28285682
Int Urol Nephrol. 2021 Dec;53(12):2493-2503
pubmed: 33797012
Curr Opin Immunol. 2015 Apr;33:23-35
pubmed: 25621841
Pathol Res Pract. 2019 Dec;215(12):152700
pubmed: 31704149
Diagnostics (Basel). 2021 Nov 21;11(11):
pubmed: 34829506
Front Oncol. 2021 Nov 11;11:746976
pubmed: 34900692
Front Oncol. 2022 Apr 06;12:851191
pubmed: 35463322
Sci Rep. 2020 Apr 10;10(1):6220
pubmed: 32277125
Protein Cell. 2019 Nov;10(11):840-845
pubmed: 31236852
Front Immunol. 2020 Oct 08;11:574271
pubmed: 33162990
J Am Soc Nephrol. 2021 Sep;32(9):2223-2241
pubmed: 34074699
Cancers (Basel). 2021 Apr 07;13(8):
pubmed: 33916925
Mol Cancer. 2019 Nov 6;18(1):155
pubmed: 31690319
BMC Cancer. 2019 Feb 13;19(1):144
pubmed: 30760245
J Hepatol. 2019 Oct;71(4):731-741
pubmed: 31173813
Cancer Drug Resist. 2020 Jul 02;3(3):454-471
pubmed: 35582435
Br J Dermatol. 2018 Jul;179(1):213-215
pubmed: 29405254
Genome Biol. 2016 Nov 17;17(1):231
pubmed: 27855702
Urology. 2019 Feb;124:168-173
pubmed: 30385260
Biomark Res. 2021 Mar 20;9(1):20
pubmed: 33743809
Proc Natl Acad Sci U S A. 2015 May 26;112(21):6682-7
pubmed: 25964334
Sci Rep. 2018 May 10;8(1):7477
pubmed: 29748622